Disease model pig exhibiting stable phenotype, and production method thereof
Inventors
Nagashima, Hiroshi • MATSUNARI, Hitomi • Watanabe, Masahito
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disease model pigs produced by nuclear transplantation, disease model pigs exhibiting stable phenotypes and production methods thereof are provided. Chimeric pigs for producing disease model pigs exhibiting stable phenotypes, genital glands thereof, and germ cells thereof are also provided. A method for producing a genetically modified disease model pig, includes: (a) transplanting a nucleus of a genetically modified cell into cytoplasm of an egg; (b) developing an obtained clonal embryo in a womb of a female pig to obtain an offspring; and mating the obtained offspring or having the offspring undergo sexual reproduction to further obtain the genetically modified offspring as a disease model pig.
Core Innovation
The invention relates to a method for producing a genetically modified pig using somatic cell nuclear transfer to obtain a clonal embryo from a genetically modified pig somatic cell. To overcome unstable or variable disease phenotypes due to somatic-cell or clone epigenetic effects, the clonal embryo is mixed with an embryo of a pig without a fetal genetic disease to yield a chimeric embryo.
The chimeric embryo is developed in the womb of a female to obtain a chimeric pig, and the genetically modified pig is obtained by mating the chimeric pig or allowing the chimeric pig to undergo sexual reproduction. The resulting phenotype is described as more stable than the phenotype in a cloned pig obtained by developing the clonal embryo, and second-generation offspring obtained by sexual reproduction are stable in phenotype because somatic-cell or clone epigenetic effects are eliminated.
The disclosure includes disease model examples in pigs, including a diabetes model using dominant-negative HNF-1αP291fsinsC, a hyperammonemia model via OTC gene disruption, and a dilated cardiomyopathy model via δ-sarcoglycan (SGCD) disruption. The chimeric embryo approaches enable production of model animals, including carrier pigs and viable animals for fatal genetic diseases.
Claims Coverage
The partial content provides three independent claims that cover producing genetically modified pigs by combining somatic cell nuclear transfer-derived clonal embryos with fetal-disease-free embryos to form chimeric embryos, followed by gestation and then mating or sexual reproduction to obtain progeny with a more stable phenotype and reduced or eliminated nuclear-transfer epigenetic effects.
Somatic-cell nuclear transfer to generate a clonal embryo and obtain a chimeric embryo by mixing with a fetal genetic disease-free embryo
The method produces an enucleated pig oocyte, transplants a nucleus of a pig somatic cell having a genetic modification into the cytoplasm to obtain a clonal embryo, and mixes the clonal embryo with an embryo of a pig without a fetal genetic disease to yield a chimeric embryo.
Gestation of the chimeric embryo to obtain a chimeric pig and sexual reproduction to obtain a genetically modified pig with a more stable phenotype
The method develops the chimeric embryo in the womb of a female pig to obtain a chimeric pig, and mates the chimeric pig or has the chimeric pig undergo sexual reproduction to obtain a genetically modified pig comprising the genetic modification, wherein the genetically modified pig further comprises a phenotype that is more stable than the phenotype in a cloned pig obtained by developing the clonal embryo in the womb of a female.
Second generation pig free of nuclear-transfer epigenetic effect present in a cloned pig
The method produces an enucleated pig oocyte, transplants a somatic cell nucleus to obtain a clonal embryo, mixes the clonal embryo with an embryo of a pig without a fetal genetic disease to yield a chimeric embryo, develops the chimeric embryo in the womb of a female pig to obtain a first generation chimeric pig, and mates the chimeric pig or has it undergo sexual reproduction to obtain a second generation pig that is free of a nuclear-transfer epigenetic effect present in a cloned pig produced by developing the clonal embryo into a cloned pig.
Together, the independent claims define an approach that uses somatic-cell nuclear transfer to form a clonal embryo from a genetically modified somatic cell, converts it into a chimeric embryo by mixing with an embryo lacking a fetal genetic disease, then uses gestation and mating or sexual reproduction so that the resulting genetically modified pigs or progeny have a phenotype that is more stable and are free of nuclear-transfer epigenetic effects compared with pigs obtained by developing the clonal embryo alone.
Stated Advantages
The phenotype in the genetically modified pig is more stable than the phenotype in a genetically modified pig obtained by developing the clonal embryo in the womb of a female to obtain a cloned pig.
A second generation pig is free of a nuclear-transfer epigenetic effect present in a cloned pig produced by developing the clonal embryo into a cloned pig.
Documented Applications
Production of disease model pigs, including diabetes model pigs using dominant-negative HNF-1αP291fsinsC, hyperammonemia model pigs via OTC gene disruption, and dilated cardiomyopathy model pigs via δ-sarcoglycan (SGCD) disruption.
Production of model animals for fatal genetic diseases using chimeric embryo approaches, including production of carrier pigs (heterozygotes) and providing genital gland/germ cells from chimeras for sexual reproduction-based propagation.
Interested in licensing this patent?